HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
IAMFIT
This study is now recruiting.
Researchers at CHOP are recruiting patients diagnosed with either acute leukemia (myeloid, lymphoid), myelodysplastic syndromes, or aplastic anemia and treated with allogeneic hematopoietic cell transplantation (HCT) within the past 6-48 months.
Research has shown that adolescents and young adults who are treated with HCT are at increased risk for skeletal muscle loss. So, the purpose of this study is to investigate if a combination of exercise training and an exercise supplement can mitigate this effect. The
supplement is called nicotinamide riboside.
Participants will be randomly assigned to 1 of 4 groups:
- Exercise + Supplement
- Exercise + Placebo
- No Exercise + Supplement
- No Exercise + Placebo
The study will provide all the exercise equipment required to complete the exercise intervention, including remote sessions.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at iamfit [at] chop.edu or 267-602-4603.
ClinicalTrials.gov Identifier
Visit Criteria
If you agree to take part, your participation will last for about up to 44 weeks and will involve 2 in-person study visits at CHOP University City Campus. You will be randomly assigned to take either the study drug: nicotinamide riboside, or a placebo for 16 weeks.
Participants will complete research testing (blood draw, body composition testing (DXA), cardio-pulmonary exercise testing (CPET), MRI (no contrast, no sedation) at the Baseline and the Follow-Up Visits. Participants will also complete a remote Interim Visit with local blood draw at the halfway point (8 weeks). Participants will be compensated for their time and effort.
